Collaboration announcement | October 1, 2025
The new collaboration agreement will enable wider access to non-invasive testing to assess the likelihood of having liver fibrosis, a globally widespread but often undiagnosed disease.
Evido collaborates with Roche in a non-exclusive distribution agreement for their LiverPRO technology, through navify Algorithm Suite. LiverPRO is a CE-certified (CE 2797) clinical decision support software intended to assess the likelihood of having liver fibrosis among adult individuals at risk of steatotic liver disease¹. This collaboration underscores Roche’s dedication to advancing digital health solutions especially for patients affected by liver disease.
Liver fibrosis is an asymptomatic and often undiagnosed disease that can lead to serious complications if not prevented or reversed in time². This collaboration aims to address this challenge by providing access to non-invasive testing during existing consultations with at-risk patients. By including LiverPRO in Roche's upcoming Liver Disease panel, we are able to expand the investigational tools available for detecting liver fibrosis, based on medically validated and certified blood-based biomarkers and algorithms, that can lead to positive patient and healthcare system impact.
Evido, a Danish health tech company, developed LiverPRO based on more than a decade of clinical research in liver disease diagnostics. We are looking forward to a strong partnership that leverages Evido’s technological and medical expertise for a fruitful collaboration!